Journal article
Effects of Persisting Emotional Impact from Child Abuse and Norepinephrine Transporter Genetic Variation on Antidepressant Efficacy in Major Depression: A Pilot Study
Ajeet Bhagat Singh, Chad A Bousman, Chee Hong Ng, Keith Byron, Michael Berk
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology | KOREAN COLL NEUROPSYCHOPHARMACOLOGY | Published : 2015
Abstract
OBJECTIVE: Previous studies suggest child abuse and serotonergic polymorphism influence depression susceptibility and antidepressant efficacy. Polymorphisms of the norepinephrine transporter (NET) may also be involved. Research in the area is possibly clouded by under reporting of abuse in researcher trials. METHODS: Adults (n=51) with major depressive disorder has 8 weeks treatment with escitalopram or venlafaxine. Abuse history was obtained, the ongoing emotional impact of which was measured with the 15-item impact of event scale (IES-15). The 17-item Hamilton Depression Rating Scale (HDRS) was applied serially. Two NET polymorphisms (rs2242446 and rs5569) were assayed, blinded to HDRS rat..
View full abstractGrants
Funding Acknowledgements
Singh AB: Consultant Psychiatrist, The Geelong Clinic, Geelong, Australia. Senior Clinical Lecturer, School of Medicine, Deakin University, Geelong, Australia. Received a research grant from Pfizer and speaker honoraria from Astra Zeneca Australia, Lilly Australia, Pfizer Australia, Lundbeck Australia, The GP Association of Geelong, and The Mental Health Professionals Network. Served as an advisor to The Australian Federal Government, Mayne Pharma, Pfizer, and Deakin University.Ng CH: Served in the Wyeth and Eli Lilly Advisory Boards, received research grant support from Wyeth and Lundbeck and speaker honoraria from Bristol-Myers Squibb, Organon, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Astra-Zenaca, Wyeth, and Pfizer.Berk M: Professor of Psychiatry, Deakin University, Professorial Research Fellow, Mental Health Research Institute, Orygen Research Centre and the University of Melbourne, consultant to Astra Zeneca, Bristol Meyers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, and Servier; is on the speaker's bureau of Astra Zeneca, Bristol Meyers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Pfizer, Sanofi, Synthlabo, Servier, Solvay, and Wyeth; has received grant/research support from Astra Zeneca, Beyond Blue, Bristol Meyers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Mayne Pharma, MBF Bioscience, National Health and Medical Research Council, Novartis, Organon, Servier, and Stanley Medical Research Foundation; and has received honoraria from Astra Zeneca, Bristol Meyers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Pfizer, Sanofi, Synthlabo, Servier, Solvay, and Wyeth.